New York City-based Lion Biotechnologies Inc, a developer of new cancer treatments, has raised $100 million in financing. The backers were Quogue Capital, OrbiMed Advisors, Frazier Healthcare Partners and Broadfin Capital. In addition to the funding, Lion has named Dr. Maria Fardis as CEO and president. Her appointment became effective June 1. Previously, she worked at Acerta Pharma where she served as the chief operating officer.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: